Abstract

ESPL1/separase, a cysteine endopeptidase, is a key player in centrosome duplication and mitotic sister chromatid separation. Aberrant expression and/or altered separase proteolytic activity are associated with centrosome amplification, aneuploidy, tumorigenesis and disease progression. Since centrosome alterations are a common and early detectable feature in patients with myelodysplastic syndrome (MDS) and cytogenetic aberrations play an important role in disease risk stratification, we examined separase activity on single cell level in 67 bone marrow samples obtained from patients with MDS, secondary acute myeloid leukemia (sAML), de novo acute myeloid leukemia (AML) and healthy controls by a flow cytometric separase activity assay. The separase activity distribution (SAD) value, a calculated measure for the occurrence of cells with prominent separase activity within the analyzed sample, was tested for correlation with the centrosome, karyotype and gene mutation status. We found higher SAD values in bone marrow cells of sAML patients than in corresponding cells of MDS patients. This concurred with an increased incidence of aberrant centrosome phenotypes in sAML vs. MDS samples. No correlation was found between SAD values and the karyotype/gene mutation status. During follow-up of four MDS patients we observed increasing SAD values after transformation to sAML, in two patients SAD values decreased during azacitidine therapy. Cell culture experiments employing MDS-L cells as an in vitro model of MDS revealed that treatment with rigosertib, a PLK1 inhibitor and therapeutic drug known to induce G2/M arrest, results in decreased SAD values. In conclusion, the appearance of cells with unusual high separase activity levels, as indicated by increased SAD values, concurs with the transformation of MDS to sAML and may reflect separase dysregulation potentially contributing to clonal evolution during MDS progression. Separase activity measurement may therefore be useful as a novel additional molecular marker for disease monitoring.

Highlights

  • Myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant oligo-clonal hematopoietic stem cell (HSC) disorders characterized by impaired growth and differentiation of hematopoietic progenitors associated with peripheral blood cytopenias and an increased risk of transformation to acute myeloid leukemia (AML) [1,2,3]

  • We investigated the context between separase activity and MDS progression by comparatively analyzing separase proteolytic activity, karyotype, centrosomal, mutational and clinical status in a total of 67 bone marrow samples derived from MDS, secondary acute myeloid leukemia (sAML), de novo AML patients and corresponding healthy control donors

  • In order to investigate the potential context between altered separase activity and MDS progression we have comparatively analyzed separase proteolytic activity, karyotype, centrosomal, mutational and clinical status in a total of 67 bone marrow samples derived from 54 patients with MDS, sAML, de novo AML and from 7 corresponding healthy control donors

Read more

Summary

Introduction

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant oligo-clonal hematopoietic stem cell (HSC) disorders characterized by impaired growth and differentiation of hematopoietic progenitors associated with peripheral blood cytopenias and an increased risk of transformation to acute myeloid leukemia (AML) [1,2,3]. Recent studies have demonstrated that MDS arise from a small population of disease-initiating HSC with initiating mutations that lead to the development of clonal hematopoiesis. Such initiating events are followed by accumulation of additional cooperating mutations including cytogenetic lesions and eventual progression to an overt clinical disease [1, 4, 5]. Despite initial clinical response to treatment with Lenalidomide and other drugs, patient’s bone marrow persistently remained clonal with rapid outgrowth of founder-, sub-, or even fully independent clones, indicating a therapy-related increased dynamic rate of clonal turnover. Taking into account the degree of cytopenia, the proportion of bone marrow blasts and the karyotype, it does not include information about somatic mutations in individual genes or other cellular aberrations that may be of predictive value [5, 7, 10, 11]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call